232 related articles for article (PubMed ID: 31073071)
21. Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India.
Bahl A; Sharma A; Raina V; Kumar L; Bakhshi S; Gupta R; Kumar R
Asia Pac J Clin Oncol; 2015 Sep; 11(3):242-52. PubMed ID: 25639656
[TBL] [Abstract][Full Text] [Related]
22. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
[TBL] [Abstract][Full Text] [Related]
23. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract][Full Text] [Related]
24. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
25. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
26. Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
Zhang MY; Othus M; Shaw C; Schonhoff KG; Halpern AB; Appelbaum J; Hendrie PC; Walter RB; Estey EH; Percival MM
Leuk Lymphoma; 2023 May; 64(5):990-996. PubMed ID: 36891630
[TBL] [Abstract][Full Text] [Related]
27. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota VK
Leuk Res; 2019 Mar; 78():45-51. PubMed ID: 30716655
[TBL] [Abstract][Full Text] [Related]
29. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
31. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
32. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Malfuson JV; Etienne A; Turlure P; de Revel T; Thomas X; Contentin N; Terré C; Rigaudeau S; Bordessoule D; Vey N; Gardin C; Dombret H;
Haematologica; 2008 Dec; 93(12):1806-13. PubMed ID: 18838471
[TBL] [Abstract][Full Text] [Related]
33. Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia.
Fattoum J; Cannas G; Elhamri M; Tigaud I; Plesa A; Heiblig M; Plesa C; Wattel E; Thomas X
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):477-83. PubMed ID: 25843415
[TBL] [Abstract][Full Text] [Related]
34. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
35. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
37. [Acute myeloid leukemia of the elderly: recent progresses in therapy].
Yamauchi T
Rinsho Ketsueki; 2018; 59(6):735-740. PubMed ID: 29973453
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.
Medeiros BC; Pandya BJ; Hadfield A; Pike J; Wilson S; Mueller C; Bui CN; Flanders SC; Rider A; Horvath Walsh LE
Curr Med Res Opin; 2019 May; 35(5):927-935. PubMed ID: 30712406
[TBL] [Abstract][Full Text] [Related]
39. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O'Connell C; Solomon SR; Pigneux A; Vey N; Hills R; Jacobsen TF; Gianella-Borradori A; Foss Ø; Vetrhusand S; Giles FJ
J Clin Oncol; 2014 Jun; 32(18):1919-26. PubMed ID: 24841975
[TBL] [Abstract][Full Text] [Related]
40. [High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia].
Medrano-Contreras J; Talavera-Piña JO; Guerrero-Rivera S; Gutiérrez-Espíndola GR; Gómez-Cortés C; Pérez-Rocha JF; Terreros-Muñoz E; Meillón-García LA
Rev Med Inst Mex Seguro Soc; 2016; 54 Suppl 2():S148-55. PubMed ID: 27561018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
